Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02437019 | Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | approved for marketing | — | — | Janssen-Cilag Farmaceutica Ltda.INDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT01606982 | Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | approved for marketing | — | — | Astellas Pharma Global Development, Inc.INDUSTRY |
| 0 |
| Feb 17, 2017 |
| clinicaltrials |
| NCT01649284 | Afatinib Expanded Access Program | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 30, 2016 | clinicaltrials |
| NCT01209650 | LUX Lung Special Access Scheme Australia Named Patient Use (NPU) | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 10, 2016 | clinicaltrials |
| NCT02589717 | An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy | approved for marketing | — | — | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01160250 | A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | approved for marketing | — | — | Genentech, Inc.INDUSTRY | 1 | Aug 6, 2015 | clinicaltrials |
| NCT02136511 | Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia | approved for marketing | — | — | Gilead SciencesINDUSTRY | 4 | Oct 28, 2014 | clinicaltrials |
| NCT01683110 | Expanded Access of Cabozantinib in Medullary Thyroid Cancer | approved for marketing | — | — | ExelixisINDUSTRY | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00905593 | Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(ENACT) | approved for marketing | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 18, 2012 | clinicaltrials |
| NCT00130897 | Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma | approved for marketing | — | — | PfizerINDUSTRY | 50 | Mar 9, 2012 | clinicaltrials |
| NCT00040625 | ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 4 | Mar 15, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Mar 20, 2017source: clinicaltrials